Abstract
In the more industrialised part of the world, sudden cardiac (arrhythmic) death has remained, throughout recent years, the leading cause of mortality. Preventing lethal arrhythmias has been a top priority in medical research and the literature abounds with reports describing the mechanisms of action of anti- or pro-arrhythmic agents and their cardiac electrophysiological effects. Studies such as the Cardiac Arrhythmia Suppression Trials (CAST-I and -II) [1], CASCADE (Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation) [2], CASH (Cardiac Arrest Study Hamburg), CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial) [3], ESVEM (Electrophysiologic Study versus Electrocardiographic Monitoring Trial) [4], CAPS (Cardiac Arrhythmia Pilot Study) and DAVIT (Danish Verapamil Infarction Trial) [5] for example, and new approaches to the classification of antiarrhythmic drugs, based on their actions on arrhythmogenic mechanisms and studies of ‘cardioprotective’ agents and potassium c...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
